Trial · NCT04620187
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NCT04620187, Phase 2, Recruiting, Dana-Farber Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas. Trials, record NCT04620187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04620187
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- NCT number
- NCT04620187
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 37 participants, estimated
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Salivary Gland Cancer, HER2 Gene Mutation
- Interventions
- Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy
- First posted
- 2020-11-06
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2 Year Disease-free survival (DFS) Rate | Time from the date of study registration to first invasive local, regional, distant recurrence, or death due to any cause assessed up to 36 months | Kaplan-Meier method will be used to estimate 2 Year Disease-free survival (DFS) Rate |
| Secondary | Adverse Events | Time from study registration to death due to any cause, or censored at date last known alive assessed up to 36 months | Evaluate adverse events for patient receiving T-DM1, defined as adverse events of all grades utilizing CTCAE v5 |
| Secondary | Overall survival (OS) Rate | Time from study registration to death due to any cause, or censored at date last known alive assessed up to 36 months | Overall Survival (OS) estimated using a Kaplan-Meier or competing risk methodology (whichever is appropriate). |
| Secondary | Distant metastatic-free survival (DMFS) Rate | Time from study registration to the earlier of the first occurrence of distant or metastatic disease, or death due to any cause assessed up to 36 months | Distant metastatic-free survival (DMFS) Rate estimated using a Kaplan-Meier or competing risk methodology (whichever is appropriate). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04620187
GET https://conductscience.org/api/trials/v1/NCT04620187/registered